SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is capturing attention as a community-driven project that is rallying behind the development of its ticker and charting integration, with supporters emphasizing its focus on organic growth and transparent tokenomics. The community is actively using social platforms to boost visibility and volume, framing the project as a long-term alternative to the volatility of other meme coin sectors.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate the impact of agentic AI competition against the company's strong fundamentals and established enterprise role. While the community remains polarized by recent volatility and technical support levels, many are focused on the upcoming product showcase as a potential catalyst to shift the narrative and challenge short interest.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending due to a major multi-year compute deal with Anthropic and an expanded capacity agreement with Meta, which have energized investor interest in the stock. While these partnerships highlight CoreWeave's role as a critical AI infrastructure provider, the community is actively debating the impact of a concurrent debt offering, weighing the massive growth potential against the implications of ongoing corporate dilution.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake is facing intense volatility as the market reacts to a strong earnings report and AI growth metrics with a sharp sell-off, highlighting concerns over high valuations and competitive pressure from emerging AI models. Investors are currently torn between the company's solid revenue growth and the broader sector-wide repricing of high-multiple SaaS stocks amid fears of AI-driven disruption.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently the focal point of intense market debate as investors weigh a recent FSD approval in the Netherlands against persistent concerns over shrinking margins and potential demand issues. While bulls point to vertical integration and future autonomous breakthroughs as long-term catalysts, the community is actively divided between those hunting for a major short squeeze and others bracing for further downside amid ongoing regulatory scrutiny.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is currently a major focus for traders as the community debates its long-term viability, with some highlighting institutional ETF accumulation and real-world payment adoption while others emphasize its prolonged underperformance relative to other assets. Discussions remain polarized, oscillating between speculation about an impending breakout driven by technical patterns and frustration over the coin's stagnant price action and lack of momentum.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is facing significant selling pressure amid a broader software sector rotation, fueled by a UBS downgrade and market-wide concerns that AI disruption may commoditize traditional IT enterprise platforms. While the community remains deeply divided between those viewing the decline as a rare value opportunity for a long-term enterprise staple and those warning of a structural breakdown in SaaS valuation models, heavy volume and RSI levels have many traders actively debating whether a capitulation bottom is finally forming.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals is capturing significant investor attention as shares experience high volatility driven by speculation around upcoming pivotal trial data for its lead oncology candidate. The community is actively debating the company's valuation relative to its cash position, while split perspectives persist on whether the recent momentum represents a genuine breakout or a speculative short-term play.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing heightened volatility and intense social media chatter following an unprecedented endorsement by President Trump, which has sparked a heated debate between retail bulls betting on a short squeeze and institutional skeptics questioning the company's valuation compared to rivals like Anthropic. The stock is currently at the center of a liquidity battle as traders weigh the impact of potential new government defense contracts against critical bearish sentiment regarding the software sector's long-term outlook.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon is seeing significant market activity as investors react to a speculative but widely discussed 12-billion-dollar acquisition rumor involving Sun Pharma. While the company's substantial debt load and history of recurring takeover chatter are fueling skepticism among some, others are drawn to the stock's potential for a significant valuation reset if a deal materializes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendat...

Immuneering (IMRX) to Release Earnings on Thursday

Immuneering (NASDAQ:IMRX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 19. (View Earnings Report at...

Immuneering's (IMRX) "Buy" Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued a "buy" rating and issued a $11.00 price objective on shares of Immuneering in a research note on Monday...

Immuneering (NASDAQ:IMRX) Raised to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Immuneering from a "sell" rating to a "hold" rating in a report on Saturday...

Monashee Investment Management LLC Makes New Investment in Immuneering Corporation $IMRX

Monashee Investment Management LLC acquired a new stake in Immuneering Corporation (NASDAQ:IMRX - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and...

Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3

Immuneering (NASDAQ:IMRX) Chief Executive Officer and co-founder Ben Zeskind told attendees at Oppenheimer's 36th Annual Healthcare Life Sciences Conference that the company is focused on improving...

Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Brokerages

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has received an average recommendation of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat reports. One...

Sanofi Invests $18.96 Million in Immuneering Corporation $IMRX

Sanofi bought a new stake in shares of Immuneering Corporation (NASDAQ:IMRX - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The...

Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven research firms that are currently covering the firm, Marketbeat reports...

Immuneering (NASDAQ:IMRX) Insider Purchases $24,990.00 in Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Harold Eugene Brakewood purchased 5,250 shares of the business's stock in a transaction dated Friday, January 16th. The shares were...

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

IMRX
Immuneering Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IMRX News

IMRXImmuneering Corp